Alaunos Therapeutics, INC. (TCRT) — SEC Filings

Overview

Alaunos Therapeutics, INC. (TCRT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $1.159 million for the three months ended September 30, 2025, a slight increase from the $1.127 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $3.283 million, an improvement from the

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 33 neutral, 2 mixed. The dominant filing sentiment for Alaunos Therapeutics, INC. is neutral.

Filing Type Overview

Alaunos Therapeutics, INC. (TCRT) has filed 23 8-K, 6 10-Q, 1 S-1, 2 DEF 14A, 1 10-K/A, 2 10-K, 3 SC 13G/A, 1 8-K/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (39)

• 8-K Filing — 8-K · Dec 23, 2025
• Alaunos Narrows 9-Month Loss, Boosts Cash Amid Strategic Shift — 10-Q · Nov 14, 2025 Risk: high
  Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $1.159 million for the three months ended September 30, 2025, a slight increase from the $1.127 million
• Alaunos Pivots to Obesity, Seeks $25M Amid Oncology Wind-Down — S-1 · Oct 22, 2025 Risk: high
  Alaunos Therapeutics, Inc. (TCRT) is undergoing a significant strategic pivot, shifting from clinical-stage oncology cell therapy to a preclinical small molecul
• Alaunos Therapeutics Files 8-K — 8-K · Aug 20, 2025 Risk: low
  Alaunos Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting an event on August 19, 2025. The filing is categorized under 'Other Events' and does not s
• Alaunos Narrows Losses, Boosts Cash Amid Nasdaq Delisting Threat — 10-Q · Aug 14, 2025 Risk: high
  Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $1.051 million for the three months ended June 30, 2025, a slight improvement from the $1.129 million n
• Alaunos Therapeutics Reports Board and Officer Changes — 8-K · Jul 22, 2025 Risk: medium
  Alaunos Therapeutics, Inc. announced on July 16, 2025, a change in its board of directors. Specifically, the company reported the departure of certain officers
• Alaunos Therapeutics Announces Board and Officer Changes — 8-K · Jul 17, 2025 Risk: medium
  Alaunos Therapeutics, Inc. announced on July 15, 2025, changes related to its board of directors and officers, including the departure of certain individuals an
• Alaunos Therapeutics Files 8-K on Security Holder Matters — 8-K · Jul 10, 2025 Risk: medium
  Alaunos Therapeutics, Inc. filed an 8-K on July 10, 2025, reporting events as of July 3, 2025. The filing indicates material modifications to the rights of secu
• Alaunos Therapeutics Faces Delisting Concerns — 8-K · Jul 2, 2025 Risk: high
  Alaunos Therapeutics, Inc. filed an 8-K on July 2, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company also disclo
• Alaunos Therapeutics Reports Material Definitive Agreement & Equity Sales — 8-K · Jun 26, 2025 Risk: medium
  Alaunos Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting on several key events as of June 24, 2025. These include entering into a material definitive
• Alaunos Therapeutics Files 8-K on Key Agreements — 8-K · Jun 10, 2025 Risk: medium
  On June 9, 2025, Alaunos Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The compa
• Alaunos Therapeutics Files 8-K on Agreements and Equity Sales — 8-K · May 23, 2025 Risk: medium
  Alaunos Therapeutics, Inc. filed an 8-K on May 23, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and financial st
• Alaunos Therapeutics Files DEF 14A for 2024 — DEF 14A · May 21, 2025 Risk: medium
  Alaunos Therapeutics, Inc. filed a DEF 14A on May 21, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other co
• Alaunos Therapeutics Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Alaunos Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key dates and ag
• Alaunos Therapeutics Files 2024 10-K/A Amendment — 10-K/A · Apr 30, 2025 Risk: medium
  Alaunos Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, formerly known as ZIOPHARM
• Alaunos Therapeutics Reports Board and Executive Changes — 8-K · Apr 18, 2025 Risk: medium
  Alaunos Therapeutics, Inc. announced on April 15, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the dep
• Alaunos Therapeutics Appoints New Chief Medical Officer — 8-K · Apr 15, 2025 Risk: medium
  Alaunos Therapeutics, Inc. announced on April 15, 2025, that its Board of Directors appointed Dr. S. Robin Cohen as Chief Medical Officer, effective April 13, 2
• Alaunos Therapeutics Files 8-K with Key Corporate Updates — 8-K · Apr 14, 2025 Risk: medium
  On April 11, 2025, Alaunos Therapeutics, Inc. filed an 8-K detailing several material events. These include the entry into and termination of material definitiv
• Alaunos Therapeutics Faces Delisting Concerns — 8-K · Apr 11, 2025 Risk: high
  Alaunos Therapeutics, Inc. filed an 8-K on April 11, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly
• Alaunos Therapeutics Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  Alaunos Therapeutics, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as ZIOPHARM
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Alaunos Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Alaunos Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and operational activities
• Alaunos Therapeutics Terminates Material Agreement — 8-K · Oct 10, 2024 Risk: medium
  Alaunos Therapeutics, Inc. announced on October 4, 2024, the termination of a material definitive agreement. The company also reported on its results of operati
• Alaunos Therapeutics Files 10-Q, Details R&D and G&A Expenses — 10-Q · Aug 14, 2024 Risk: medium
  Alaunos Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the six months ended J
• Alaunos Therapeutics Files 8-K/A Amendment — 8-K/A · Jul 17, 2024 Risk: low
  Alaunos Therapeutics, Inc. filed an amendment (8-K/A) on July 17, 2024, to a previous report dated July 16, 2024. This amendment pertains to "Other Events" and
• NuScale Power to Acquire Alaunos Therapeutics — 8-K · Jul 16, 2024 Risk: medium
  Alaunos Therapeutics, Inc. announced on July 16, 2024, that it has entered into a definitive agreement to be acquired by NuScale Power Corporation. The transact
• Alaunos Therapeutics to be acquired by 3D Medicines for $100M — 8-K · Jun 21, 2024 Risk: medium
  Alaunos Therapeutics, Inc. announced on June 19, 2024, that it has entered into a definitive agreement to be acquired by 3D Medicines Inc. for approximately $10
• Alaunos Therapeutics Files 8-K: Corporate Changes and Shareholder Votes — 8-K · Jun 12, 2024 Risk: medium
  On June 6, 2024, Alaunos Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced a significant amendment to its certificate o
• Alaunos Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: medium
  Alaunos Therapeutics, Inc. (TCRT) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Alaunos Therapeutics, Inc. (TCRT) filed a 10-Q for the quarter e
• Alaunos Therapeutics Announces 2024 Annual Meeting and Proxy Statement — DEF 14A · Apr 26, 2024 Risk: low
  Alaunos Therapeutics, Inc. (TCRT) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The 2024 annual meeting of stockholders for Alaunos Therapeu
• Alaunos Therapeutics Files 2023 Annual Report on Form 10-K — 10-K · Apr 1, 2024 Risk: medium
  Alaunos Therapeutics, Inc. (TCRT) filed a Annual Report (10-K) with the SEC on April 1, 2024. Alaunos Therapeutics, Inc. (TCRT) filed its 2023 Form 10-K on Apri
• Alaunos Therapeutics Reports Executive Changes and Compensation Updates — 8-K · Feb 22, 2024 Risk: medium
  Alaunos Therapeutics, Inc. filed an 8-K on February 22, 2024, reporting events from February 15, 2024. The filing pertains to the departure or election of direc
• Alaunos Therapeutics Files 8-K on Feb 16 Event — 8-K · Feb 20, 2024 Risk: low
  Alaunos Therapeutics, Inc. filed an 8-K on February 20, 2024, reporting an event that occurred on February 16, 2024. The filing indicates a current report pursu
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Alaunos Therapeutics Amends Charter Documents — 8-K · Feb 1, 2024
  Alaunos Therapeutics, Inc. (TCRT) filed an 8-K on February 1, 2024, reporting an event on January 31, 2024, related to amendments to its Articles of Incorporati
• Alaunos Therapeutics Files 8-K, Confirms Nasdaq Listing — 8-K · Jan 29, 2024
  Alaunos Therapeutics, Inc. (TCRT) filed an 8-K on January 29, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates a ro
• Alaunos Therapeutics Files Standard 8-K; No Major Changes Reported — 8-K · Jan 22, 2024
  Alaunos Therapeutics, Inc. filed an 8-K on January 22, 2024, reporting an event that occurred on January 20, 2024. This filing is a standard 'Current Report' an
• Alaunos Therapeutics Reports Executive Changes & Compensation on Dec 29 — 8-K · Jan 2, 2024
  Alaunos Therapeutics, Inc. filed an 8-K on January 2, 2024, reporting an event that occurred on December 29, 2023. The filing indicates a 'Departure of Director

Risk Profile

Risk Assessment: Of TCRT's 31 recent filings, 5 were flagged as high-risk, 22 as medium-risk, and 4 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Alaunos Therapeutics, INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $2K
• Net Income: -$3.283M
• EPS: -$1.84
• Debt-to-Equity: 0.33
• Cash Position: $1.938M
• Operating Margin: N/A
• Total Assets: $3.724M
• Total Debt: $0.921M

Key Executives

• Holger Weis
• Scott Doney, Esq.
• Dr. S. Robin Cohen

Industry Context

Alaunos Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on developing novel therapies. The sector is characterized by long development cycles, significant R&D investment, and high failure rates. Companies often rely on external financing and strategic partnerships to advance their pipelines.

Top Tags

corporate-governance (11) · management-change (4) · filing (4) · corporate-action (4) · 10-Q (4) · Biotechnology (3) · material-agreement (3) · equity-sale (3) · amendment (3) · regulatory-filing (3)

Key Numbers

• Net Loss (Q3 2025): $1.159M — Increased from $1.127M in Q3 2024, indicating continued operational losses.
• Net Loss (YTD 2025): $3.283M — Improved from $3.937M in YTD 2024, showing some cost control or reduced activity.
• Cash and Cash Equivalents: $1.938M — Increased from $1.091M at Dec 31, 2024, providing a short-term liquidity boost.
• Stockholders' Equity: $2.803M — Maintains compliance with Nasdaq's $2.5M minimum, but future compliance is uncertain.
• R&D Expenses (YTD 2025): $1.002M — Significantly increased from $448K in YTD 2024, reflecting investment in the obesity program.
• G&A Expenses (YTD 2025): $2.318M — Decreased from $3.615M in YTD 2024, indicating efforts to reduce overhead.
• Accumulated Deficit: $923.729M — Highlights the company's long history of losses and need for substantial future profitability.
• Outstanding Shares: 2,231,829 — As of November 14, 2025, indicating potential for dilution from future capital raises.
• Series A-1 Preferred Stock Sale: $500K — Part of financing activities to bolster cash reserves.
• Series A-2 Preferred Stock Sale: $850K — Further capital raised to support operations.
• Potential Equity Purchase Agreement Proceeds: $25.0M — Maximum amount Alaunos may receive from Mast Hill Fund, L.P. over 24 months, crucial for funding the new obesity program.
• Net Loss (6 months): $2.1M — Net loss for the six months ended June 30, 2025, highlighting ongoing operational losses despite cost reductions.
• Workforce Reduction: 95% — Percentage of workforce reduced by the end of 2023 as part of strategic reprioritization and cost-cutting measures.
• R&D Expenses (Cancer, 6 months): $0.3M — Research and development expenses for cancer programs for the six months ended June 30, 2025, down from $11.7 million in 2023, reflecting the pivot.
• Warrant Exercise Price: $4.00 — Initial exercise price per share for the common stock purchase warrant issued to Mast Hill, indicating a potential future capital infusion.

Related Companies

ALAO · SMR · AL耺

Frequently Asked Questions